Evidence Hub

To Be or Not to Be: Amiodarone as Both Savior and Foe-A Therapeutic Paradox in Atrial Fibrillation Management and Ventricular Arrhythmia Associated with Amiodarone-Induced Thyrotoxicosis

Amielan M, Zalewska-Adamiec M, Bachórzewska-Gajewska H, Dobrzycki S

Life (Basel, Switzerland), 2026

Abstract

Amiodarone-induced thyrotoxicosis (AIT) is a serious thyroid dysfunction that represents a significant complication of pharmacological therapy in cardiology patients. The development of AIT can substantially complicate the management of cardiac arrhythmias, posing a major clinical challenge. We present the case of a patient in whom amiodarone was initially effective in the treatment of atrial fibrillation but subsequently led to type II amiodarone-induced thyrotoxicosis and exacerbation of the atrial arrhythmia. This case highlights the need for regular monitoring of patients treated with amiodarone, the challenges of managing arrhythmias in the setting of AIT, and the importance of close collaboration between cardiologists and endocrinologists in the diagnosis and treatment of AIT.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free